Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Dec;18(4):298-312.
doi: 10.15430/jcp.2013.18.4.298.

Ovarian cancer biomarker discovery based on genomic approaches

Jung-Yun Lee  1 , Hee Seung Kim  1 , Dong Hoon Suh  1 , Mi-Kyung Kim  1 , Hyun Hoon Chung  1 , Yong-Sang Song  2
Affiliations
Review

Ovarian cancer biomarker discovery based on genomic approaches

Jung-Yun Lee et al. J Cancer Prev. 2013 Dec.

Abstract

Ovarian cancer presents at an advanced stage in more than 75% of patients. Early detection has great promise to improve clinical outcomes. Although the advancing proteomic technologies led to the discovery of numerous ovarian cancer biomarkers, no screening method has been recommended for early detection of ovarian cancer. Complexity and heterogeneity of ovarian carcinogenesis is a major obstacle to discover biomarkers. As cancer arises due to accumulation of genetic change, understanding the close connection between genetic changes and ovarian carcinogenesis would provide the opportunity to find novel gene-level ovarian cancer biomarkers. In this review, we summarize the various gene-based biomarkers by genomic technologies, including inherited gene mutations, epigenetic changes, and differential gene expression. In addition, we suggest the strategy to discover novel gene-based biomarkers with recently introduced next generation sequencing.

Keywords: Cancer biomarker; Early detection; Genes; Genomic technologies; Ovarian cancer.

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Flow diagram for strategy to discover the novel gene-based biomarkers for high-grade serous ovarian carcinoma. STIC, serous tubal intraepithelial carcinoma.
See this image and copyright information in PMC

References

    1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62:10–29. - PubMed
    1. Heintz AP, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92. - PubMed
    1. Suh DH, Kim K, Kim JW. Major clinical research advances in gynecologic cancer in 2011. J Gynecol Oncol. 2012;23:53–64. - PMC - PubMed
    1. Zhang B, Cai FF, Zhong XY. An overview of biomarkers for the ovarian cancer diagnosis. Eur J Obstet Gynecol Reprod Biol. 2012;158:119–23. - PubMed
    1. Bast RC., Jr Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Trans Am Clin Climatol Assoc. 2004;115:233–47. discussion 247–238. - PMC - PubMed

LinkOut - more resources